Loading the comparison…
Loading the comparison…
Recovery & Repair
The most-discussed healing peptide, built on a stomach-protein fragment.
Recovery & Repair
A four-peptide repair blend: GLOW plus the anti-inflammatory KPV.
BPC-157 is not FDA-approved and rated 2/5 for evidence; KLOW is not FDA-approved and rated 2/5. They have a similar amount of human evidence. Both are banned in sport by WADA. Both are used for recovery & repair goals.
| Compare | BPC-157 The most-discussed healing peptide, built on a stomach-protein fragment. | KLOW A four-peptide repair blend: GLOW plus the anti-inflammatory KPV. |
|---|---|---|
| Category | Recovery & Repair | Recovery & Repair |
| Evidence | 2/5Dozens of rodent studies; only tiny human pilot data (e.g. knee pain retrospective, IV safety pilot). | 2/5No studies of the blend itself. Rated no higher than its weakest core parts (BPC-157, TB-500, KPV are mostly animal data). |
| FDA status | Not FDA-approved | Not FDA-approved |
| WADA (sport) | Banned | Banned |
| Also known as | Body Protection Compound-157, Bepecin, PL 14736 | KLOW blend, BPC-157 + TB-500 + GHK-Cu + KPV |
| How it works | Appears to up-regulate growth-factor receptors (VEGFR2, growth hormone receptor), promote new blood vessel formation (angiogenesis), and modulate nitric-oxide signaling. Exact human pharmacology is not established. | Combines four mechanisms: BPC-157 (local repair and blood-vessel growth), TB-500 (cell migration via actin), GHK-Cu (copper delivery and collagen signaling) and KPV (NF-κB inflammation blocking). Whether they add together, or interfere, has not been studied. |
| Half-life | Short (hours); effects thought to be local + signaling driven | Mixed: each component differs; all are short-acting signals |
| Commonly reported doses |
|
|
| Route | Subcutaneous, near injury site | Subcutaneous |
| Good once mixed | ~28 days in the fridge | ~28 days in the fridge |
| Top side effects |
|
|
| Lowest research-listing price per mg | $2.40 (10 mg vial, 40% off) | $0.75 (80 mg vial, 40% off) |
| Latest lab purity | 99.61% (lot BP0002) | 99.85% (lot KLW0002) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about BPC-157 and KLOW. It answers from these same pages, with links back here.
BPC-157 is not FDA-approved and rated 2/5 for evidence; KLOW is not FDA-approved and rated 2/5. They have a similar amount of human evidence. Both are banned in sport by WADA. Both are used for recovery & repair goals.
BPC-157: Not FDA-approved. KLOW: Not FDA-approved. Regulations change, so confirm with the FDA.
BPC-157 is rated 2 out of 5: Dozens of rodent studies; only tiny human pilot data (e.g. knee pain retrospective, IV safety pilot). KLOW is rated 2 out of 5: No studies of the blend itself. Rated no higher than its weakest core parts (BPC-157, TB-500, KPV are mostly animal data). The scale is explained on our methodology page.
BPC-157 is banned by WADA, by name or as part of a named class. KLOW is banned by WADA, by name or as part of a named class.